Actively Recruiting
Tick-borne Encephalitis and Borrelial Antibodies in Serum
Led by University Medical Centre Ljubljana · Updated on 2025-03-25
80
Participants Needed
1
Research Sites
695 weeks
Total Duration
On this page
Sponsors
U
University Medical Centre Ljubljana
Lead Sponsor
U
University of Ljubljana School of Medicine, Slovenia
Collaborating Sponsor
AI-Summary
What this Trial Is About
In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick. In clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne encephalitis antibodies in serum of a patient with compatible clinical presentation and cerebrospinal pleocytosis. Patients with Lyme meningitis or meningoradiculitis also have cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not attest Lyme neuroborreliosis. Patients with tick-borne encephalitis and positive borrelial antibodies in serum, but not fulfilling criteria for Lyme neuroborreliosis, are often being treated with antibiotics in several European countries due to the possibility of double infection. The investigators hypothesise that such patients do not benefit from antibiotics. Such an approach may appear safe regarding the possibility of borrelial infection, however it can also be associated with detrimental consequences such as antibiotic related adverse reactions, negative epidemiological impact on bacterial resistance, and intravenous catheter related complications.
CONDITIONS
Official Title
Tick-borne Encephalitis and Borrelial Antibodies in Serum
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Clinical picture compatible with tick-borne encephalitis
- Clear cerebrospinal fluid
- Cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid >5 x 10^6/L)
- Positive serum IgM and IgG antibodies against tick-borne encephalitis virus
- Positive serum IgG antibodies against Lyme borreliae
You will not qualify if you...
- Isolation of B. burgdorferi sensu lato from cerebrospinal fluid
- Positive intrathecal borrelial antibody production index
- Seroconversion of borrelial IgG antibodies
- Presence of erythema migrans and/or borrelial lymphocytoma in the last month
- Bannwarth syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Ljubljana
Ljubljana, Slovenia
Actively Recruiting
Research Team
D
Daša Stupica, MD PhD
CONTACT
M
Maša Velušček, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here